Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05282277 · ClinicalTrials.gov registry record · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
A Phase 4 study of Depression and Psychosis, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT05282277 is a Phase 4 study of Depression and Psychosis that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 103 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05282277, a Phase 4 study of Depression and Psychosis, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous positron emission tomography and functional magnetic resonance imaging (PET-MR).
Conditions Studied
Interventions
- DRUG Transdermal Estradiol
- DRUG Micronized Progesterone
- DRUG Matching Placebo Patch
- DRUG Raclopride C11
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05282277
The ClinicalTrials.gov registry entry for NCT05282277 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 4 interventions - of which Transdermal Estradiol is the first listed.
NCT05282277 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05282277 about?
NCT05282277 is a clinical study titled "Examining the Effects of Estradiol on Neural and Molecular Response to Reward". This proposal will examine the effects of estradiol administration on perimenopausal-onset (PO) anhedonia and psychosis symptoms as well as on brain function using simultaneous positron emission tomography and functional magnetic resonance imaging (PET-MR).
What is the current status of trial NCT05282277?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2022-04-20. Estimated completion is 2026-12-31.
What conditions does trial NCT05282277 study?
This clinical trial studies the following conditions: Depression, Psychosis, Anhedonia.
What interventions are being tested in trial NCT05282277?
The interventions under investigation include: Transdermal Estradiol (DRUG), Micronized Progesterone (DRUG), Matching Placebo Patch (DRUG), Raclopride C11 (DRUG).
Who is sponsoring clinical trial NCT05282277?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05282277 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
-
Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.